VTGN
MaterialsVistaGen Therapeutics Inc
$0.61+0.01 (+1.72%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving VTGN Today?
No stock-specific AI insight has been generated for VTGN yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$24M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume239K
Avg Volume (10D)—
Shares Outstanding39.6M
VTGN News
20 articles- Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety DisorderYahoo Finance·May 8, 2026
- Vistagen Receives FDA "Study May Proceed" Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to MenopauseYahoo Finance·Apr 22, 2026
- Vistagen to Participate in Upcoming Investor ConferencesYahoo Finance·Mar 3, 2026
- Vistagen to Participate in the 46th Annual TD Cowen Healthcare ConferenceYahoo Finance·Feb 25, 2026
- VistaGen Therapeutics, Inc. Q3 2026 Earnings Call SummaryMoby·Feb 13, 2026
- Vistagen Therapeutics Inc (VTGN) Q3 2026 Earnings Call Highlights: Progress in Clinical Trials ...Yahoo Finance·Feb 13, 2026
- VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue EstimatesYahoo Finance·Feb 12, 2026
- Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate UpdateYahoo Finance·Feb 12, 2026
- Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026Yahoo Finance·Feb 4, 2026
- US Equity Markets Fall as Technology Stocks Slump Amid Oracle ConcernsYahoo Finance·Dec 17, 2025
- Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety DisorderYahoo Finance·Dec 17, 2025
- Vistagen Appoints Nick Tressler as Chief Financial OfficerYahoo Finance·Dec 1, 2025
- Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual MeetingYahoo Finance·Nov 26, 2025
- Vistagen Therapeutics Inc (VTGN) Q2 2026 Earnings Call Highlights: Progress in Palisade 3 Trial ...Yahoo Finance·Nov 14, 2025
- VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Lags Revenue EstimatesYahoo Finance·Nov 13, 2025
- Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate UpdateYahoo Finance·Nov 13, 2025
- XOMA Royalty (XOMA) Reports Q3 Loss, Lags Revenue EstimatesYahoo Finance·Nov 12, 2025
- Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025Yahoo Finance·Nov 10, 2025
- Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue EstimatesYahoo Finance·Nov 5, 2025
- Vistagen to Participate in Stifel Healthcare Conference 2025Yahoo Finance·Nov 5, 2025
All 20 articles loaded
Price Data
Open$0.60
Previous Close$0.60
Day High$0.61
Day Low$0.59
52 Week High—
52 Week Low—
Fundamentals
Market Cap$24M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume239K
Avg Volume (10D)—
Shares Outstanding39.6M
About VistaGen Therapeutics Inc
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—